 Connection
Bradley Dixon to Treatment Outcome
This is a "connection" page, showing publications Bradley Dixon has written about Treatment Outcome.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.227 |
|
|
|
-
Dixon BP, Bomback AS, Rich C, Hakimi Z, Huang M, Gordon K, Wojciechowski P, Margas W, Chang R, Duh MS, Caravaca-Fontán F, Fakhouri F. Pegcetacoplan Versus Iptacopan for the Treatment of Patients with C3 Glomerulopathy: Indirect Treatment Comparisons. Adv Ther. 2026 Aug; 43(8):3385-3402.
Score: 0.083
-
Denburg MR, Goodwin Davies AJ, Maltenfort MG, Mitsnefes MM, Flynn JT, Neu AM, Dixon BP, Glenn DA, Gluck CA, Harshman LA, Katsoufis CP, Leonard MB, Modi ZJ, Pan CG, Patel HP, Patterson LT, Verghese PS, Wilson AC, Jovanovska A, Levondosky R, Levondosky M, Dickinson K, Wieand K, Razzaghi H, Li L, Chen Y, Forrest CB. Comparative Effectiveness of Antihypertensive Medications in Children With Chronic Kidney Disease. JAMA Pediatr. 2026 May 01; 180(5):546-555.
Score: 0.021
-
Fakhouri F, Bomback AS, Ariceta G, Delmas Y, Dixon BP, Gale DP, Greenbaum LA, Han SH, Isbel N, Le Quintrec M, Licht C, Mastrangelo A, Mizuno M, Neves de Holanda MI, Pickering MC, Remuzzi G, Van De Kar N, Vivarelli M, Walker PD, Wallace D, Zecher D, Francois C, Deschatelets P, Li L, Wang Z, Abad-Franch L, Kinnman N, López-Lázaro L, Szamosi J, Nester CM. Trial of Pegcetacoplan in C3 Glomerulopathy and Immune-Complex MPGN. N Engl J Med. 2025 Dec 04; 393(22):2210-2220.
Score: 0.020
-
Atkinson MA, Chang JC, Davies AG, Maltenfort M, Luna IY, Scobell R, Mitsnefes M, Stotter BR, Dharnidharka VR, Dixon BP, Flynn JT, Gluck C, Kallash M, Smoyer WE, Razzaghi H, Bailey LC, Furth SL, Forrest CB, Denburg MR, Wenderfer SE. Using a multi-institutional pediatric learning health system to characterize induction therapy for incident lupus nephritis in children. Pediatr Nephrol. 2026 Apr; 41(4):1045-1053.
Score: 0.020
-
Denburg MR, Hirabayashi K, Davies AG, Razzaghi H, Dharnidharka VR, Dixon BP, Flynn JT, Gluck CA, Mitsnefes MM, Smoyer WE, Furth SL, Forrest CB. Utilization of anti-CD20 antibodies for treatment of childhood nephrotic syndrome, 2010 to 2022. Pediatr Nephrol. 2025 Oct; 40(10):3121-3127.
Score: 0.019
-
Dharnidharka VR, Scobell RR, Kallash M, Davies AJG, Marchesani N, Maltenfort MG, Walther L, Kelton M, Bock M, Blanchette E, Stone HK, Gluck C, Hullekes F, Riella LV, Smoyer WE, Mitsnefes M, Dixon BP, Flynn JT, Somers MJG, Forrest CB, Furth S, Denburg MR. Clinical characteristics and favorable treatment responses of recurrent focal segmental glomerulosclerosis or steroid-resistant nephrotic syndrome in children after kidney transplantation. Pediatr Nephrol. 2024 Nov; 39(11):3317-3331.
Score: 0.018
-
Goodwin Davies AJ, Xiao R, Razzaghi H, Bailey LC, Utidjian L, Gluck C, Eckrich D, Dixon BP, Deakyne Davies SJ, Flynn JT, Ranade D, Smoyer WE, Kitzmiller M, Dharnidharka VR, Magnusen B, Mitsnefes M, Somers M, Claes DJ, Burrows EK, Luna IY, Furth SL, Forrest CB, Denburg MR. Skeletal Outcomes in Children and Young Adults with Glomerular Disease. J Am Soc Nephrol. 2022 12; 33(12):2233-2246.
Score: 0.016
-
Siroky BJ, Towbin AJ, Trout AT, Schäfer H, Thamann AR, Agricola KD, Tudor C, Capal J, Dixon BP, Krueger DA, Franz DN. Improvement in Renal Cystic Disease of Tuberous Sclerosis Complex After Treatment with Mammalian Target of Rapamycin Inhibitor. J Pediatr. 2017 08; 187:318-322.e2.
Score: 0.011
-
Fraga-Rodriguez GM, Brió-Sanagustin S, Turón-Viñas E, Dixon BP, Carreras-González E. Eculizumab in a child with atypical haemolytic uraemic syndrome and haemophagocytic lymphohistiocytosis triggered by cytomegalovirus infection. BMJ Case Rep. 2017 Apr 26; 2017.
Score: 0.011
-
Lo MM, Mo JQ, Dixon BP, Czech KA. Disseminated histoplasmosis associated with hemophagocytic lymphohistiocytosis in kidney transplant recipients. Am J Transplant. 2010 Mar; 10(3):687-91.
Score: 0.007
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|